替加环素对台湾地区气单胞菌、弧菌及沙门菌临床分离株的体外活性
In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
作者信息
Liu Chia-Ying, Huang Yu-Tsung, Liao Chun-Hsing, Hsueh Po-Ren
机构信息
Section of Infectious Diseases, Department of Internal Medicine, Far-Eastern Memorial Hospital, Taiwan.
出版信息
Antimicrob Agents Chemother. 2008 Jul;52(7):2677-9. doi: 10.1128/AAC.00002-08. Epub 2008 May 12.
Abstract
All 198 Salmonella isolates (58.6% of isolates were resistant to tetracycline), 92 Vibrio isolates (4.4% of isolates were resistant to tetracycline), and 200 of 201 Aeromonas isolates (39.3% of isolates were resistant to tetracycline; 1 A. caviae isolate had a tigecycline MIC of 4 mug/ml) in our study were susceptible to tigecycline, by U. S. Food and Drug Administration criteria for Enterobacteriaceae.
摘要
根据美国食品药品监督管理局针对肠杆菌科的标准，我们研究中的所有198株沙门氏菌分离株（58.6%的分离株对四环素耐药）、92株弧菌分离株（4.4%的分离株对四环素耐药）以及201株气单胞菌分离株中的200株（39.3%的分离株对四环素耐药；1株豚鼠气单胞菌分离株的替加环素最低抑菌浓度为4μg/ml）对替加环素敏感。
相似文献
1
In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.替加环素对台湾地区气单胞菌、弧菌及沙门菌临床分离株的体外活性
Antimicrob Agents Chemother. 2008 Jul;52(7):2677-9. doi: 10.1128/AAC.00002-08. Epub 2008 May 12.
2
In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus.替加环素对创伤弧菌的体外和体内抗菌活性。
J Microbiol Immunol Infect. 2018 Feb;51(1):76-81. doi: 10.1016/j.jmii.2016.04.009. Epub 2016 May 13.
3
Minimum inhibitory concentration of carbapenems and tigecycline against Salmonella spp.碳青霉烯类和替加环素对沙门氏菌的最低抑菌浓度
J Med Microbiol. 2009 Mar;58(Pt 3):337-341. doi: 10.1099/jmm.0.47853-0.
4
In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator.体外和体内使用头孢曲松作为对照比较替加环素对临床非伤寒沙门氏菌分离株的细胞内杀伤作用。
Antimicrob Agents Chemother. 2011 Jun;55(6):2755-9. doi: 10.1128/AAC.01807-10. Epub 2011 Mar 14.
5
The tetA gene decreases tigecycline sensitivity of Salmonella enterica isolates.tetA 基因降低肠沙门氏菌分离株对替加环素的敏感性。
Int J Antimicrob Agents. 2013 Aug;42(2):133-40. doi: 10.1016/j.ijantimicag.2013.04.017. Epub 2013 Jun 6.
6
Bacterial aetiology of diarrhoeal diseases and antimicrobial resistance in Dhaka, Bangladesh, 2005-2008.2005-2008 年孟加拉国达卡腹泻病的细菌病因学和抗菌药物耐药性。
Epidemiol Infect. 2012 Sep;140(9):1678-84. doi: 10.1017/S0950268811002135. Epub 2011 Nov 1.
7
Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.替加环素针对包括耐四环素分离株在内的全球肠杆菌科菌株集合的活性测试。
Diagn Microbiol Infect Dis. 2005 Jul;52(3):209-13. doi: 10.1016/j.diagmicrobio.2005.06.010.
8
Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.作为替加环素评估与监测试验的一部分，2004年至2015年间从拉丁美洲地区收集的革兰氏阳性和革兰氏阴性生物体的抗菌药敏性。
Ann Clin Microbiol Antimicrob. 2017 Jul 12;16(1):50. doi: 10.1186/s12941-017-0222-0.
9
Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).替加环素活性的监测，检测了来自全球（北美、欧洲、拉丁美洲和亚太地区）收集的临床分离株（2016 年）。
Int J Antimicrob Agents. 2018 Jun;51(6):848-853. doi: 10.1016/j.ijantimicag.2018.01.006. Epub 2018 Feb 2.
10
Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M).屎肠球菌临床分离株中的替加环素耐药性是由质粒编码的四环素决定簇 tet(L) 和 tet(M) 的上调介导的。
J Antimicrob Chemother. 2016 Apr;71(4):871-81. doi: 10.1093/jac/dkv420. Epub 2015 Dec 18.
引用本文的文献
1
The Impact of Cefuroxime Susceptibility on Necrotizing Fasciitis Outcomes.头孢呋辛敏感性对坏死性筋膜炎治疗结果的影响。
Microorganisms. 2023 Nov 15;11(11):2776. doi: 10.3390/microorganisms11112776.
2
Antimicrobial resistance among clinical non-O1/non-O139 isolates: systematic review and meta-analysis.临床非 O1/非 O139 分离株的抗菌药物耐药性：系统评价和荟萃分析。
Pathog Glob Health. 2023 May;117(3):235-244. doi: 10.1080/20477724.2022.2114620. Epub 2022 Aug 19.
3
Epidemiology, Serogroups and Resistance of During a 15-Year Period (2006-2020) in Kuwait.科威特15年期间（2006 - 2020年）的流行病学、血清群及耐药性情况
Infect Drug Resist. 2021 Nov 25;14:4957-4966. doi: 10.2147/IDR.S340116. eCollection 2021.
4
Synergy and Activity of Tigecycline-Ciprofloxacin Combination Therapy against Vibrio vulnificus Sepsis.替加环素-环丙沙星联合治疗对创伤弧菌败血症的协同作用和活性。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00310-19. Print 2019 Oct.
5
Multidrug-resistant (MDR) Aeromonas recovered from the metropolitan area of Valencia (Spain): diseases spectrum and prevalence in the environment.从西班牙巴伦西亚大都市区分离出的多重耐药气单胞菌：疾病谱及环境中的流行情况
Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):137-145. doi: 10.1007/s10096-014-2210-z. Epub 2014 Aug 2.
6
Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.碳青霉烯类药物对临床非伤寒沙门氏菌分离株的作用：体外和体内动物研究的结果。
Antimicrob Agents Chemother. 2012 Jun;56(6):2916-22. doi: 10.1128/AAC.00110-12. Epub 2012 Apr 2.
7
Which antibiotics and breakpoints should be used for Aeromonas susceptibility testing? Considerations from a comparison of agar dilution and disk diffusion methods using Enterobacteriaceae breakpoints.应当使用哪些抗生素和折点进行气单胞菌药敏试验？使用肠杆菌科折点比较琼脂稀释法和纸片扩散法的考虑因素。
Eur J Clin Microbiol Infect Dis. 2012 Sep;31(9):2369-77. doi: 10.1007/s10096-012-1578-x. Epub 2012 Feb 27.
8
In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator.体外和体内使用头孢曲松作为对照比较替加环素对临床非伤寒沙门氏菌分离株的细胞内杀伤作用。
Antimicrob Agents Chemother. 2011 Jun;55(6):2755-9. doi: 10.1128/AAC.01807-10. Epub 2011 Mar 14.
9
In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006.2001-2006 年台湾一家医学中心腹腔内感染相关细菌分离株的体外莫西沙星和替加环素活性。
Eur J Clin Microbiol Infect Dis. 2009 Dec;28(12):1437-42. doi: 10.1007/s10096-009-0801-x. Epub 2009 Sep 8.
本文引用的文献
1
EUCAST technical note on tigecycline.欧洲临床微生物与感染性疾病学会（EUCAST）关于替加环素的技术说明。
Clin Microbiol Infect. 2006 Nov;12(11):1147-9. doi: 10.1111/j.1469-0691.2006.01578.x.
2
Prognostic factors and antibiotics in Vibrio vulnificus septicemia.创伤弧菌败血症的预后因素与抗生素
Arch Intern Med. 2006 Oct 23;166(19):2117-23. doi: 10.1001/archinte.166.19.2117.
3
Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.产超广谱β-内酰胺酶肠杆菌科细菌中的抗生素共耐药性及替加环素的体外活性。
Antimicrob Agents Chemother. 2006 Aug;50(8):2695-9. doi: 10.1128/AAC.00155-06.
4
Tigecycline: a critical analysis.替加环素：批判性分析
Clin Infect Dis. 2006 Aug 15;43(4):518-24. doi: 10.1086/505494. Epub 2006 Jun 26.
5
Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.替加环素治疗皮肤及皮肤结构感染的安全性和有效性：与万古霉素-氨曲南的双盲3期对照研究结果
Antimicrob Agents Chemother. 2005 Nov;49(11):4658-66. doi: 10.1128/AAC.49.11.4658-4666.2005.
6
Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.替加环素针对包括耐四环素分离株在内的全球肠杆菌科菌株集合的活性测试。
Diagn Microbiol Infect Dis. 2005 Jul;52(3):209-13. doi: 10.1016/j.diagmicrobio.2005.06.010.
7
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.替加环素单药治疗与万古霉素联合氨曲南治疗复杂性皮肤及皮肤结构感染患者的疗效和安全性比较：一项3期随机双盲试验的结果
Int J Infect Dis. 2005 Sep;9(5):251-61. doi: 10.1016/j.ijid.2005.05.003.
8
Bacterial food-borne illness outbreaks in northern Taiwan, 1995-2001.1995 - 2001年台湾北部细菌性食源性疾病暴发情况
J Infect Chemother. 2005 Jun;11(3):146-51. doi: 10.1007/s10156-005-0383-1.
9
Increasing ceftriaxone resistance in Salmonella isolates from a university hospital in Taiwan.台湾一所大学医院分离出的沙门氏菌对头孢曲松的耐药性增加。
J Antimicrob Chemother. 2005 Jun;55(6):846-52. doi: 10.1093/jac/dki116. Epub 2005 May 4.
10
Vibrio vulnificus in Taiwan.台湾的创伤弧菌。
Emerg Infect Dis. 2004 Aug;10(8):1363-8. doi: 10.3201/eid1008.040047.
Zotero 插件